This observational study is looking at how well allogeneic hematopoietic stem cell transplants (alloHCT) work for people with multiple myeloma, a type of blood cancer. AlloHCT is the only treatment that might cure multiple myeloma, but it can have serious side effects. Researchers will compare the outcomes of people who receive an alloHCT with those who receive an autologous HCT (autoHCT), which uses your own stem cells. To join, you must be a Medicare beneficiary with Stage II or III multiple myeloma or primary plasma cell leukemia, and be eligible for an alloHCT at a US transplant center. The main goal is to see how many people are still alive five years after their transplant.

Study design

This is an observational study that aims to enroll 544 participants. It compares outcomes for those receiving allogeneic HCT with a matched group receiving autologous HCT.

What's involved

You would need to agree to submit comprehensive clinical data about your health before and after the transplant.

Compensation

Not stated in the trial record.

Follow-up

The study will track participants' survival for five years after their transplant.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.